Finally, we discuss the translational potential of these approaches and the remaining challenges, including tumour heterogeneity, immunotoxicity and dynamic regulation within the tumour microenvironment, that must be addressed to optimize MHC‐targeted interventions in cancer immunotherapy. The gene discussed is HLA-C; the disease is cancer.